MRVI vs. ARES

In the year-to-date period, MRVI achieves a -58.72% return, which is significantly lower than ARES's -5.78% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Maravai LifeSciences Holdings, Inc. (MRVI) and Ares Management Corporation (ARES). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MRVI Sharpe Ratio is -0.91, which is lower than the ARES Sharpe Ratio of 0.46. The chart below compares the historical Sharpe Ratios of MRVI and ARES, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

MRVI has not paid dividends to shareholders, while ARES's dividend yield for the trailing twelve months is around 2.36%.

The maximum MRVI drawdown since its inception was -97.16%, which is greater than ARES's maximum drawdown of -45.85%. Use the drawdown chart below to compare losses from any high point for MRVI and ARES.

Maravai LifeSciences Holdings, Inc. (MRVI) has a higher volatility of 21.20% compared to Ares Management Corporation (ARES) at 9.84%. This indicates that MRVI's price experiences larger fluctuations and is considered to be riskier than ARES based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Maravai LifeSciences Holdings, Inc. and Ares Management Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.